[The trends in new drugs for the prostate cancer].
Sato
Naohide
N
Department of Urology, Ichihara Hospital, School of Medicine, Teikyo University.
Masai
Motoyuki
M
D000256:Adenoviridae; D000726:Androgen Antagonists; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001388:Aziridines; D019496:Cancer Vaccines; D015195:Drug Design; D005480:Flurbiprofen; D015316:Genetic Therapy; D005822:Genetic Vectors; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D017273:Goserelin; D006801:Humans; D016729:Leuprolide; D008297:Male; D016376:Oligonucleotides, Antisense; D000077544:Panitumumab; D017430:Prostate-Specific Antigen / Q000276:immunology; D011471:Prostatic Neoplasms / Q000628:therapy*
D000726:Androgen Antagonists; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D001388:Aziridines; D019496:Cancer Vaccines; D016376:Oligonucleotides, Antisense; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D005480:Flurbiprofen; D000077544:Panitumumab; C100099:tretazicar; D017430:Prostate-Specific Antigen; D016729:Leuprolide